Status:
TERMINATED
Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
RATIONALE: Fluorine F 18 FEQA may be an effective radioactive drug to use with positron emission tomography (PET) scans. PURPOSE: This clinical trial is studying the use of fluorine F 18 FEQA in pati...
Detailed Description
OBJECTIVES: * Determine the biodistribution of fluorine F 18 FEQA in patients with stage III or IV non-small cell lung cancer (NSCLC) and in healthy participants. * Determine whether fluorine F 18 FE...
Eligibility Criteria
Inclusion
- Must meet 1 of the following criteria:
- Diagnosis of non-small cell lung cancer by CT scan, bone scan, or biopsy
- Stage III or IV disease
- Clinically assessed with
- Healthy participant
Exclusion
Key Trial Info
Start Date :
May 4 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 15 2008
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00444223
Start Date
May 4 2004
End Date
May 15 2008
Last Update
August 5 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States, 90095-1781